Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HANS H HERFARTH

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1538246574
CMS profile
748946
Location
CHAPEL HILL, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$13,500.00

6 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $13,500.00 6

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Gilead Sciences, Inc. $9,750.00 3
Eli Lilly and Company $3,600.00 2
Biogen, Inc. $150.00 1

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HANS H HERFARTH

NPI 1538246574 · CMS profile ID 748946

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

CHAPEL HILL, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1538246574?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HANS H HERFARTH, NPI 1538246574, CMS profile ID 748946. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1538246574?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). HANS H HERFARTH, NPI 1538246574, CMS profile ID 748946. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1538246574?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
HANS H HERFARTH, NPI 1538246574, CMS profile ID 748946, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1538246574?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

6 matching records · $13,500.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 6 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–6 of 6.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Eli Lilly and Company $2,800.0008/21/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1186654843 CMS
Gilead Sciences, Inc. $2,850.0006/24/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1234351494 CMS
Biogen, Inc. $150.0005/27/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1208351752 CMS
Gilead Sciences, Inc. $4,500.0002/11/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1234351060 CMS
Eli Lilly and Company $800.0001/17/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1186654845 CMS
Gilead Sciences, Inc. $2,400.0001/14/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1234351666 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $10,664.39 10
PY2020 $19,041.44 14
PY2021 $7,950.00 5
PY2022 $5,950.00 3
PY2023 $3,236.00 3
PY2024 $17,266.46 16
PY2025 $13,500.00 6

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $3,575.00 2
PY2025 Principal investigator $12,323.55 21
PY2024 Recipient $319,533.00 4
PY2024 Principal investigator $59,545.89 24
PY2023 Principal investigator $224,917.53 43
PY2022 Principal investigator $370,819.65 53
PY2021 Principal investigator $392,748.05 56
PY2020 Principal investigator $481,918.70 51
PY2019 Recipient $4,200.00 1
PY2019 Principal investigator $373,860.96 46

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

47 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $17,457.72 12/23/2019 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA PEL HILL
A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease No dispute reported 06/30/2026 654263813
Principal investigator 1 AbbVie, Inc. $2,070.00 12/18/2019 Non-covered Recipient Entity
University Of North Carolina At Chapel Hill
M14-327 No dispute reported 06/30/2026 647581509
Principal investigator 1 AbbVie, Inc. $6,649.60 12/03/2019 Non-covered Recipient Entity
University Of North Carolina At Chapel Hill
M14-327 No dispute reported 06/30/2026 647581511
Principal investigator 1 Eli Lilly and Company $286.00 11/30/2019 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A MULTICENTER, OPEN-LABEL, POST MARKETING CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH GENERALIZED PUSTULAR PSORIASIS AND ERYTHRODERMIC PSORIASIS No dispute reported 06/30/2026 654285353
Principal investigator 1 Eli Lilly and Company $286.00 11/30/2019 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 654285845
Principal investigator 1 AbbVie, Inc. $1,465.60 11/04/2019 Non-covered Recipient Entity
University Of North Carolina At Chapel Hill
M14-327 No dispute reported 06/30/2026 647581513
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,774.30 10/16/2019 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
P3 AC VDZ to ADA in UC N=658, 2 arms, US-EU No dispute reported 06/30/2026 686167251
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $150.30 10/15/2019 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
A Phase 3b Open-label Study to Determine the Long-term Safety and Efficacy of Subcutaneous Vedolizumab in Patients with Ulcerative Colitis UC No dispute reported 06/30/2026 686167167
Principal investigator 1 Janssen Research & Development, LLC $14,007.36 10/07/2019 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA PEL HILL
A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease No dispute reported 06/30/2026 654263811
Principal investigator 1 AbbVie, Inc. $1,350.40 09/30/2019 Non-covered Recipient Entity
University Of North Carolina At Chapel Hill
M14-327 No dispute reported 06/30/2026 647581507
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,628.00 09/17/2019 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-Center Trial of Efficacy and Safety of Entyvio Vedolizumab in Subjects with Chronic Pouchitis No dispute reported 06/30/2026 686167255
Principal investigator 1 Janssen Research & Development, LLC $6,114.00 09/02/2019 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA PEL HILL
A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease No dispute reported 06/30/2026 654263809
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,336.00 08/12/2019 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-Center Trial of Efficacy and Safety of Entyvio Vedolizumab in Subjects with Chronic Pouchitis No dispute reported 06/30/2026 686167157
Principal investigator 1 AbbVie, Inc. $2,700.80 08/08/2019 Non-covered Recipient Entity
University Of North Carolina At Chapel Hill
M14-327 No dispute reported 06/30/2026 647581547
Principal investigator 1 Janssen Research & Development, LLC $3,247.28 07/29/2019 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA PEL HILL
A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease No dispute reported 06/30/2026 654263807
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 07/18/2019 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA PEL HILL
A Phase 2a Randomized, Double-blind, Active-controlled, Parallel-group, Multicenter, Proof-of-concept Clinical Study to Evaluate the Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 654263805
Principal investigator 1 AbbVie, Inc. $10,000.00 07/16/2019 Non-covered Recipient Entity
University Of North Carolina At Chapel Hill
M16-000 No dispute reported 06/30/2026 647581515
Principal investigator 1 AbbVie, Inc. $6,777.60 07/02/2019 Non-covered Recipient Entity
University Of North Carolina At Chapel Hill
M14-327 No dispute reported 06/30/2026 647581541
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $750.00 07/01/2019 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
P3 AC VDZ to ADA in UC N=658, 2 arms, US-EU No dispute reported 06/30/2026 686167253
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,035.00 06/17/2019 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
SC P3 CD Study No dispute reported 06/30/2026 686167161
Principal investigator 1 AbbVie, Inc. $1,465.60 05/29/2019 Non-covered Recipient Entity
University Of North Carolina At Chapel Hill
M14-327 No dispute reported 06/30/2026 647581533
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 05/24/2019 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA PEL HILL
A Phase 2a Randomized, Double-blind, Active-controlled, Parallel-group, Multicenter, Proof-of-concept Clinical Study to Evaluate the Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 654263803
Recipient Otsuka Pharmaceutical Development & Commercialization, Inc. $4,200.00 05/20/2019 Covered Recipient Physician A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT TRIAL TO ASSESS THE EFFICACY AND SAFETY OF ORALLY ADMINISTERED OPS-2071 FOR 12 WEEKS IN SUBJECTS WITH CROHNS DISEASE SHOWING SYMPTOMS OF ACTIVE INFLAMMATION DESPITE ONGOING TREATMENT No dispute reported 06/30/2026 696049961
Principal investigator 1 Bausch Health US, LLC $2,325.00 05/08/2019 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA
A DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, MULTIREGIONAL, ONE YEAR STUDY TO ASSESS THE EFFICACY AND SAFETY OF TWICE DAILY ORAL RIFAXIMIN DELAYED RELEASE TABLETS FOR INDUCTION OF CLINICAL REMISSION WITH ENDOSCOPIC RESPONSE AT 16 WEEKS FOLLOWED BY CLINICAL AND ENDOSCOPIC REMISSION AT 52 WEEKS IN SUBJECTS WITH ACTIVE MODERATE CROHNS DISEASE No dispute reported 06/30/2026 684363449
Principal investigator 1 AbbVie, Inc. $6,777.60 05/06/2019 Non-covered Recipient Entity
University Of North Carolina At Chapel Hill
M14-327 No dispute reported 06/30/2026 647581535
Principal investigator 1 AbbVie, Inc. $1,350.40 03/26/2019 Non-covered Recipient Entity
University Of North Carolina At Chapel Hill
M14-327 No dispute reported 06/30/2026 647581519
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 03/18/2019 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA PEL HILL
A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease No dispute reported 06/30/2026 654263801
Principal investigator 1 AbbVie, Inc. $1,856.00 03/13/2019 Non-covered Recipient Entity
University Of North Carolina At Chapel Hill
M14-327 No dispute reported 06/30/2026 647581521
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $334.00 03/13/2019 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
A Phase 3b Open-label Study to Determine the Long-term Safety and Efficacy of Subcutaneous Vedolizumab in Patients with Ulcerative Colitis UC No dispute reported 06/30/2026 686167165
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $334.00 03/11/2019 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
SC P3 CD Study No dispute reported 06/30/2026 686167159
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 03/07/2019 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
P3 AC VDZ to ADA in UC N=658, 2 arms, US-EU No dispute reported 06/30/2026 686167163
Principal investigator 1 Janssen Research & Development, LLC $6,600.00 02/25/2019 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA PEL HILL
A Phase 2a Randomized, Double-blind, Active-controlled, Parallel-group, Multicenter, Proof-of-concept Clinical Study to Evaluate the Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 654263799
Principal investigator 1 AbbVie, Inc. $2,700.80 02/01/2019 Non-covered Recipient Entity
University Of North Carolina At Chapel Hill
M14-327 No dispute reported 06/30/2026 647581517
Principal investigator 1 Eli Lilly and Company $110.00 01/22/2019 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LY2439821 TO ETANERCEPT AND PLACEBO IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 654285065
Principal investigator 1 Eli Lilly and Company $110.00 01/22/2019 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A 24-WEEK MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO FUMARIC ACID ESTERS AND METHOTREXATE IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS WHO ARE NAIVE TO SYSTEMIC TREATMENT WITH AN EXTENSION PERIOD No dispute reported 06/30/2026 654285067
Principal investigator 1 Eli Lilly and Company $110.00 01/22/2019 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A PHASE 3, MULTICENTER STUDY WITH A 36-WEEK OPEN-LABEL PERIOD FOLLOWED BY A RANDOMIZED DOUBLE-BLIND WITHDRAWAL PERIOD FROM WEEK 36 TO WEEK 104 TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF IXEKIZUMAB -LY2439821- 80 MG EVERY 2 WEEKS IN BIOLOGIC DISEASE MODIFYING ANTIRHEUMATIC DRUG-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS No dispute reported 06/30/2026 654285077
Principal investigator 1 Eli Lilly and Company $110.00 01/22/2019 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED 16 WEEK STUDY FOLLOWED BY LONG TERM EVALUATION OF EFFICACY AND SAFETY OF IXEKIZUMAB LY2439821 IN TNFI EXPERIENCED PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 654285113
Principal investigator 1 Eli Lilly and Company $396.00 01/22/2019 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A MULTICENTER LONG-TERM EXTENSION STUDY OF 104 WEEKS INCLUDING A DOUBLE BLIND PLACEBO CONTROLLED 40 WEEK RANDOMIZED WITHDRAWAL RETREATMENT PERIOD TO EVALUATE THE MAINTENANCE OF TREATMENT EFFECT OF IXEKIZUMAB LY2439821 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 654285191
Principal investigator 1 Eli Lilly and Company $110.00 01/22/2019 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A MULTICENTER STUDY WITH A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED INDUCTION DOSING PERIOD FOLLOWED BY A RANDOMIZED MAINTENANCE DOSING PERIOD AND A LONG TERM EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF LY2439821 IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 654285213
Principal investigator 1 Eli Lilly and Company $110.00 01/22/2019 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A 12 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LY2439821 TO ETANERCEPT AND PLACEBO IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WITH A LONG TERM EXTENSION PERIOD No dispute reported 06/30/2026 654285217
Principal investigator 1 Eli Lilly and Company $396.00 01/22/2019 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY OF IXEKIZUMAB IN PATIENTS FROM 6 TO LESS THAN 18 YEARS OF AGE WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 654285219
Principal investigator 1 Eli Lilly and Company $110.00 01/22/2019 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE AND PLACEBO-CONTROLLED 16-WEEK STUDY FOLLOWED BY LONG-TERM EVALUATION OF EFFICACY AND SAFETY OF IXEKIZUMAB -LY2439821- IN BDMARD-NAIVE PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 654285221
Principal investigator 1 Eli Lilly and Company $110.00 01/22/2019 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A 52 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF IXEKIZUMAB LY2439821 IN BDMARD NAIVE PATIENTS WITH NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 654285291
Principal investigator 1 Eli Lilly and Company $396.00 01/22/2019 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A MULTICENTER STUDY WITH A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION DOSING PERIOD FOLLOWED BY A RANDOMIZED MAINTENANCE DOSING PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF LY2439821 IN CHINESE PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 654285831
Principal investigator 1 PFIZER INC. $250,000.00 01/14/2019 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA
EFFICACY OF TOFACITINIB IN PATIENTS WITH UC No dispute reported 06/30/2026 671686427
Principal investigator 1 AbbVie, Inc. $2,498.00 01/10/2019 Non-covered Recipient Entity
University Of North Carolina At Chapel Hill
M14-327 No dispute reported 06/30/2026 647581525
Principal investigator 1 AbbVie, Inc. $1,465.60 01/03/2019 Non-covered Recipient Entity
University Of North Carolina At Chapel Hill
M14-327 No dispute reported 06/30/2026 647581527